ASX Announcement 30 January 2026
Optiscan Imaging Ltd (ASX:OIL)

APPENDIX 4C
QUARTERLY ACTIVITIES & CASHFLOW REPORT
QUARTER ENDED 31 DECEMBER 2025

Optiscan Imaging Limited (ASX:OIL) ('**Optiscan**' or the '**Company**'), a leader in medical imaging using confocal laser endomicroscopy, is pleased to announce its Appendix 4C Quarterly Cashflow report and business update for the quarter ended 31 December 2025 (the **'Quarter'**). All financial results are in Australian dollars and are unaudited.

Highlights for the Quarter

- Optiscan partnered with Australian Clinical Labs (ACL) to advance digital pathology innovation and deployment through utilising Optiscan's InForm® digital pathology platform.
- Optiscan initiated its first in-human head and neck cancer imaging study at St John of God Murdoch Hospital in Perth to:
    - Utilise Optiscan's InVue® precision surgery device, and
    - In collaboration with ACL, to utilise the InForm® digital pathology device.
- Significant progress was made across multiple clinical studies toward collection of images for FDA regulatory submissions.
- Dr. Farah delivered the keynote address at the 2025 Mayo Clinic Beahrs Surgical Innovation Summit, sharing Optiscan's vision for digital pathology and precision surgery.
- Cash receipts from customers increased to $0.377m in the Quarter, more than double the total receipts over the previous three quarters.

Optiscan's Chief Executive Officer and Managing Director, Dr. Camile Farah, commented:

"Optiscan has experienced tremendous momentum over the December 2025 quarter – and so too has the pathology-related health care segments it is targeting."

"Optiscan's team can be proud of its many achievements over the Quarter. The Company's growing list of clinical agreements with a host of tier-1 partners demonstrates the value in the strong ecosystem and relationships we have built over the years. These partnerships are built not only on the time and effort invested in nurturing them, but also on the trust earned through our ongoing commitment to advancing Optiscan's technology platform and continually enhancing our product suite. The collaboration with Australian Clinical Labs announced in the Quarter is an exciting development. It will see us deploy our

InForm® device to a high-throughput ACL laboratory, in the process helping drive adoption and innovation in digital pathology."

"From a broader digital pathology perspective, it is exciting for Optiscan to be key part of the new treatment options taking shape, and the decision by leading healthcare institutions like Mayo Clinic to focus heavily on this health care segment. Such commitment was clearly evident at the Mayo Clinic Beahrs Surgical Innovation Summit which generated a stream of digital pathology-related conversations amongst medical device and healthcare professionals. From pathology to precision surgery and medicine, the implications are significant especially when one considers the developments in AI and telepathology in which Optiscan has made great strides."

Optiscan's Innovative Digital Pathology Vision – Real-time, Digital, and at the Point of Care

Optiscan's Digital Pathology solution differentiates itself from current practices by bringing pathology to the forefront of patient care compared to being a back-end process. With real-time digital imaging at the cellular level, surgeons and pathologists have the ability to see cells live when decisions need to be made and not days or weeks later.

Keynote Address on Digital Pathology at Mayo Clinic

This is the vision that was shared at the Mayo Clinic Beahrs Surgical Innovation Summit in November 2025, through the keynote address by Optiscan CEO & MD Dr. Farah to the assembled Mayo Clinic surgical and pathology teams, investors, strategics and other entrepreneurs. The CEO of Mayo Clinic Digital Pathology, James (Jim) Rogers III, provided an inside look at Mayo Clinic's approach to capturing digital pathology's transformative potential at this same Summit, reaffirming the future direction of this promising sector. Both parties continue to work together to explore new avenues for collaboration in this space.

Partnering with Australian Clinical Labs (ACL) to Advance Digital Pathology Innovation and Deployment

Moving from vision to operations, Optiscan has partnered with Australian Clinical Labs (ACL) to support the deployment and testing of its InForm® digital pathology platform. ACL's status as a leading provider of hospital-based pathology services in Australia will enable Optiscan to validate the InForm® device in real-world conditions and collect imaging data from a broad range of human tissues and pathologies.

This Strategic Collaboration Agreement (the **'Agreement'**) between Optiscan and ACL, which is for three years, will provide benefits to both parties on multiple fronts (see announcement dated 10 November 2025). Firstly, it will support regulatory submissions through building an image data bank of human tissues and associated pathologies. This data will assist in providing a robust regulatory submission for the Company, preparatory work for which is currently underway in Australia and the US.

In addition, this Agreement will help advance commercial readiness of InForm®. By working alongside highly trained pathologists and technicians at one of ACL's flagship anatomical pathology laboratories, testing and validation of the use case for Optiscan's digital pathology platform in real-world, high throughput pathology

workflows will be delivered. From a commercial perspective, this arrangement is expected to strengthen the business case for using InForm®, and highlight which modelling results in superior efficiencies and savings throughout the anatomical pathology workflow.

From ACL's perspective, this partnership demonstrates their commitment to innovation and clinical excellence. ACL's Medical Director and Chief Pathologist, Dr Tony Landgren said: "This opportunity has the potential to enhance diagnostic workflows with real-time, data-driven insights that supports faster, more accurate decision making."

Optiscan looks forward to delivery of the positive outcomes anticipated from this partnership, which will further strengthen the Company's efforts to be ready to bridge innovative technological solutions with real-life medical and patient care.

Advancing Multiple Clinical Studies in Preparation for US FDA Regulatory Submission

The 2026 calendar year will be pivotal for Optiscan, as the Company prepares for multiple US FDA regulatory submissions for its devices and associated use cases, specifically:

- InVue® for precision surgery
- InForm® for digital pathology, and
- InSpecta® for veterinary medicine.

In preparation for these submissions, the Company has partnered with highly regarded clinical and industry partners to conduct clinical studies, which will provide the necessary clinical data to support these regulatory submissions. Below is a progress summary of the clinical studies that are underway or being planned for the year.

1. Breast Clinical Study at the Royal Melbourne Hospital Gathers Pace

   The clinical study "Assessment of Breast Cancer Margin with Confocal Laser Endomicroscopy" at the Royal Melbourne Hospital has continued throughout the Quarter, with the completion of the first seven (7) of 50 cases (with 10 cases completed as of 30 January 2026), which includes imaging with the InVue® (precision surgery) and InForm® (digital pathology) devices. Recruitment thus far has been intentionally methodical and systematic, enabling the team to optimise protocol execution and enhance operational efficiency, all while ensuring strict adherence to protocol requirements and regulatory standards.

   The recruitment of patients will accelerate in the next quarter, as the Company moves to increase its capacity with two additional clinical research assistants, who will undertake data collection and analysis, and through the phased commencement of a second clinical study site at Frances Perry House. These measures will fast-track recruitment towards the planned total of 50 patients by end of financial year in readiness for FDA submission in the second half of calendar year 2026.

2. Head and Neck Cancer Clinical Study Launched at St John of God Murdoch Hospital

   During the Quarter, Optiscan initiated the first in-human head and neck cancer imaging study utilising the Company's InVue® and InForm® devices, which will be undertaken at St John of God

Murdoch Hospital in Perth. The study is led by prominent Perth head and neck cancer surgeon Dr Chady Sader and is expected to comprise a total of 50 patients.

Head and neck cancers, which encompass cancers of the mouth and oropharynx (including lips, tongue, cheeks, sinuses, floor of the mouth, throat, and hard palate) are very complex in nature. A patient's chances of survival largely depend on how early the cancer is found and whether surgery can successfully remove all of it with clear margins. Current surgical practices and tools can be improved to provide clearer margins. Optiscan's InVue® device provides high-resolution sub-cellular imaging of any soft tissue during surgery and enables surgeons to make immediate informed decisions when evaluating a region of interest for complete excision.

This clinical study is being undertaken in partnership with Australian Clinical Labs (ACL), who is partnering to examine pathology specimens using Optiscan's InForm® digital pathology device. The dual design of this study is anticipated to both accelerate clinical data gathering and strengthen the multiple regulatory submissions being pursued. Delivery of these data gathering- and submissions-related goals should assist in further developing the Company's oral cancer AI algorithms that are anticipated to enhance the future treatment of head and neck cancers.

3. Anatomical Pathology Study Initiated at Australian Clinical Labs

During the Quarter, Optiscan finalised preparations for its Anatomical Pathology study in collaboration with ACL utilising the Company's InForm® device to build an image data bank of human tissues and associated pathologies. Subsequent to the end of the Quarter, the Company imaged its first three (3) cases comprising gastrointestinal tissue samples (a benign polyp, a suspected adenoma, and an adenocarcinoma) on the first day of imaging at ACL's Subiaco laboratory. This study will proceed quickly with dedicated imaging staff now on site in Perth. This study is expected to result in hundreds of imaging sets as the Company builds its data bank of images, a portion of which will form part of its FDA submission later in the year.

4. Gastrointestinal Clinical Study at University Medical Center Mainz

Further to pilot work already undertaken with Optiscan's current generation preclinical device ViewnVivo®, a full submission has been made to the University Medical Center Mainz ethics committee in Germany to undertake an observational imaging study in gastrointestinal (GI) tissues at that hospital; one of Europe's leading gastroenterology centres. The study will collect data from 50 patients undergoing upper and lower GI endoscopy procedures and provide images to support ongoing product development activities for the development of the Company's next generation flexible endomicroscope as part of a Cooperative Research Centres Project between Optiscan, Monash University, and Capgemini funded by the Australian Federal Government.

5. US-Based Clinical Studies in the Pipeline

In the US, ongoing preparations are being conducted with our clinical collaborators at the Mayo Clinic for various clinical studies to support US FDA regulatory submissions for the Company's three clinical devices, which will utilise Optiscan's InVue® (precision surgery), InForm® (digital pathology), and InVivage® (oral imaging) devices.

Regulatory Discussions with the FDA

As the Company prepares to lodge FDA submissions over calendar year 2026 for its three medical devices (InVue®, InForm®, and InSpecta®), the team is working closely with regulatory experts and the FDA to ensure all regulatory requirements are up to date and documentation is aligned with current FDA guidelines and standards. Importantly, meetings are being held with the FDA to discuss proposed regulatory pathways, indications for use, and clinical data collection parameters. This feedback is being incorporated into clinical studies to ensure optimum clinical data is collected to support these regulatory submissions.

Advancement of Product Development, Testing and Certification

Product Refinements and Pre-Compliance Testing get Underway

During the Quarter, progress was made across multiple projects aimed at meeting regulatory compliance, improving usability and reliability, and increasing readiness for upcoming clinical studies. These encompassed:

a) Delivery of substantial enhancements to the Company's InVue® and InForm® software platforms, including updated user interfaces that offer improved clarity and more intuitive navigation. These software platforms have undergone testing, increasing confidence in their suitability for clinical use, and have subsequently been deployed in Australian clinical sites.
b) Improvements made to the physical design of the systems' probes, which will make the probes more durable and effective in real-world use specifically aimed at withstanding the repeated sterilisation and disinfection procedures required in hospital use. These probes are now deployed in clinical studies in Australia, and being manufactured for US clinical studies for delivery next quarter.
c) Pre-compliance testing across the device range, which has yielded positive results, with ongoing tests to continue over the next quarter in line with FDA requirements. Specifically, these include electrical and electromagnetic compatibility testing in the first instance.
d) Further user evaluation and testing on the cloud-based telepathology platform, which provided valuable feedback and opportunities for refinement of both the device interface and the associated cloud portal, with plans in place to address these enhancements in future development phases with the Company's Canadian-based software partners, Prolucid Technologies.
e) The completion of detailed design trade off analyses to guide key technical decisions for the next generation flexible GI system in partnership with Capgemini. System requirements and high-level architectural designs are anticipated over the next quarter.
f) The provision of Annotated GI images to our partner Monash University, allowing them to prepare the dataset which will support future machine learning model training and help develop the GI system's long-term AI capabilities.
g) Progress with prototyping of accessories required for hardware integration of the Company's probes with robotic surgical devices as part of the ongoing Know-How agreement with the Mayo Clinic. This project will move into the pre-clinical testing phase in the next quarter, which will be undertaken at Mayo Clinic's Florida campus in Jacksonville, and is on track.

Sales Pipeline and Commercialisation Efforts

InSpecta® - Commercialising for the Future

Optiscan's Customer team continued refining the commercialisation plan for InSpecta®, with significant headway made in finalising its sales and marketing plans for the veterinary device. The Team which is being led by the CEO in the interim, subsequent to the departure of Belinda Williamson, has continued to gather market research intelligence in the veterinary medicine sector working with US-based veterinary consultants, and through showcasing of the Company's InSpecta® device at the American College of Veterinary Surgeons (ACVS) Surgery Summit in September 2025, where the team directly engaged with veterinary surgeons who were evaluating intraoperative diagnostic technologies. Follow-up meetings were made with ACVS surgical influencers and pathology stakeholders over the Quarter, strengthening relationships with key decision makers in preparation for commercial launch later in the 2026 calendar year. Subsequent to the end of the Quarter, the Company exhibited at the Veterinary Meeting & Expo (VMX); one of the largest US veterinary medicine exhibitions, taking place in Florida USA in January 2026. The Company continued to build its pipeline of interested customers for its InSpecta® device, while refining its go-to-market strategy and commercialisation plan. Additional US-based resources have been engaged to support these efforts, with an eye on securing a US-based commercialisation lead as the launch of the InSpecta® device approaches.

ViewnVivo® - Positioned for the Life Sciences Sector

USA: During the Quarter, Optiscan strengthened its academic and clinical footprint through engagement with five Tier-1 academic institutions, multiple long-standing ViewnVivo® users and surgical Key Opinion Leaders (KOL). The team participated in a Life Science Exhibits (LSE) event at Memorial Sloan Kettering Cancer Center (MSKCC), enabling engagement with clinical, research and industry stakeholders. The Company continues to revise its business strategy in the US for its preclinical life sciences product as new insights and feedback are assessed, and as the Company prepares for commercial launch of its clinical devices over the coming year.

Europe: Business development efforts in Europe continued over the Quarter with Optiscan's outsourced business development team leading to several interested parties seeking quotations. The Company continues with its exploratory work to better understand the market demand in Europe for its life sciences product before committing significant resources to that market. Continued efforts are being made to increase lead generation over the coming quarters. A review of the European market has commenced and will be concluded in the next quarter.

China: Optiscan continues to work closely with its China distributor, Biotimes Technology Limited, to provide support for their lead generation pipeline. Market conditions in China have been difficult, with significant delay in local researchers obtaining government funding for purchase of capital equipment. The Company will continue to monitor this situation considering its other operational demands. A review of the Chinese sales efforts will be undertaken in the next quarter.

Public Relations and Market Engagement Initiatives

Mayo Clinic Keynote Address

Dr Farah delivered the keynote address at the 2025 Mayo Clinic Beahrs Surgical Innovation Summit on 18 November 2025. The focus of his address was Digital Pathology, with James (Jim) Rogers III, CEO of Mayo Clinic Digital Pathology, and Dr Farah sharing expert insights on its impact on the future of clinical and surgical decision-making. Optiscan's vision - utilising InForm® and InVue® to see live cellular images whether during surgery or through telepathology - was shared with an audience made up of Mayo Clinic surgeons, pathologists and administrators, thought leaders, and various leading multinational medical device companies. Optiscan and the Mayo Clinic continue to explore avenues for collaboration in the digital pathology space, with ongoing discussions underway exploring the potential utility of the InForm® platform in furthering the Mayo Clinic's transformation of its digital pathology services.

Other Market Engagement Activities

Optiscan continued its active engagement with media, investors, and key industry stakeholders as part of ongoing efforts to enhance the Company's public profile and communicate its strategic objectives. Notable initiatives included:

- The MedTech Conference Interview with Joe Mullings
  Discussed how Optiscan's revolutionary imaging technology is transforming digital pathology and precision surgery.
- Stockhead Interview: Inside the new study tackling complex head & neck cancers
  Discussed the new clinical study targeting head and neck cancers at St John of God Murdoch Hospital in Perth.
- Optiscan Investor Webinar with Q&A
  Discussed current and upcoming clinical-and-regulatory-related activities, updates on the breast cancer study, and an overview of the Collaboration Agreement with Australian Clinical Labs (ACL).
- The Stock Network's ASX Gems Investment Conference: Healthcare Spotlight
  Presented Optiscan to potential new investors, covering the Company's product pipeline, commercialisation phases, and future direction.
- Lectures at the University of Minnesota College of Veterinary Medicine
  Covered insights into the role of real-time cellular imaging in advancing veterinary medicine.

People and Culture

During the Quarter, Optiscan added to its team, as it accelerates efforts to advance its strategic growth objectives. The Company welcomed two new Clinical Research Assistants based in Melbourne, to provide additional support to the increasing number of clinical studies underway and planned. This is aimed at accelerating data collection and image analysis which is crucial for timely FDA regulatory submissions.

The Company's Quality Assurance staff made significant progress over the last Quarter in implementing the new Electronic Quality Management System (eQMS). Migration from legacy systems is advanced, with the majority being successfully executed, which will streamline the documentation process in preparation for

FDA review tasks. Looking forward, the focus will be on using the eQMS for newly implemented processes, closing remaining legacy actions, and leveraging the new eQMS reporting to support proactive risk management, audit preparedness and continuous improvement initiatives. The Company's new eQMS is a central component of FDA regulatory readiness, and is on track for deployment in the next quarter, as FDA regulatory documentation is prepared for submission to the Agency during the year.

Corporate Update and Outlook

As the first half of the financial year concluded this Quarter, there have been notable advances in the clinical and regulatory space. The recently announced study on head and neck cancer at St John of God, taking place in collaboration with ACL, is evidence of the strong partnerships the Company has with industry and healthcare providers, aimed at furthering its strategic objective of commercial deployment.

On top of this support from industry partners, Optiscan has continued to receive strong backing from existing shareholders, as evidenced by their participation in last quarter's capital raising. The latter issue bolstered the Company's cash balance at the end of the Quarter to $17.71m.

From a commercial perspective, sales receipts from customers this Quarter of $0.38m is higher than that to the prior three quarters combined of $0.18m. This increased cash inflow partially offsets the higher research and development costs incurred this Quarter of ($1.31m). Overall, net cash outflow from operating activities declined this Quarter to ($1.99m), compared to ($2.14m) last quarter. Cash outflows from investing activities rose to ($0.15m), primarily attributable to the acquisition of specialised equipment for clinical studies and the implementation of timely computer and network upgrades essential for maintaining efficient operations.

As the FY26 year progresses, the focus on obtaining product validation through clinical evidence remains the Company's number one priority. The team has already delivered here, with the initiation of multiple clinical studies, with more set to commence over the coming quarters. In time, increased experience and efficiencies will be realised, which will help deliver accumulation of the required clinical data for FDA regulatory submissions. The Company remains confident that work done to date along with planned future initiatives will provide all the prerequisites needed to lodge the required regulatory submissions in the 2026 calendar year.

Note: All related party payments noted in Section 6 of the accompanying Appendix 4C during the Quarter relate to the payment of executive and non-executive director's fees, salaries and superannuation payments.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
T: +61 3 9538 3333
E: ceo@optiscan.com

Media & Investor Enquiries
The Capital Network
Julia Maguire
T: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn, X or Instagram.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

OPTISCAN IMAGING LIMITED

ABN	**Quarter ended ("current quarter")**
81 077 771 987	31 DECEMBER 2025

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (6 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	377	516
1.2	Payments for		
	(a) research and development	(1,316)	(2,494)
	(b) product manufacturing and operating costs	(232)	(474)
	(c) advertising and marketing	(35)	(94)
	(d) leased assets	-	-
	(e) staff costs	(870)	(1,531)
	(f) administration and corporate costs	(94)	(282)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	180	227
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(1,990)**	**(4,132)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(154)	(169)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (term deposits > 3 months maturity)	-	-
2.6	**Net cash from / (used in) investing activities**	**(154)**	**(169)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	17,751
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(42)	(112)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(30)	(62)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (payments for lease liabilities)	(58)	(113)
3.10	**Net cash from / (used in) financing activities**	**(130)**	**17,464**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	19,988	4,553
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,990)	(4,132)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(154)	(169)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (6 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(130)	17,464
4.5	Effect of movement in exchange rates on cash held	(2)	(4)
4.6	**Cash and cash equivalents at end of period**	**17,712**	**17,712**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	4,712	3,988
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (short-term deposit)	13,000	16,000
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**17,712**	**19,988**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(284)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

N/A

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,990)
8.2	Cash and cash equivalents at quarter end (item 4.6)	17,712
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	17,712
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	8.9

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

30 January 2026

Date: .....

The Board of Directors

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.